Publicacións en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (44)

2024

  1. Cross-Validation of Risk Scores for Patients Undergoing Transcatheter Edge-to-Edge Repair for Mitral Regurgitation

    Journal of the Society for Cardiovascular Angiography and Interventions, Vol. 3, Núm. 2

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

    Nature Genetics, Vol. 55, Núm. 12, pp. 2065-2074

  3. Complications related to the Cook–Swartz implantable Doppler probe use in head and neck microvascular reconstruction: a systematic review

    European Archives of Oto-Rhino-Laryngology, Vol. 280, Núm. 1, pp. 23-37

  4. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

    American Journal of Human Genetics, Vol. 110, Núm. 7, pp. 1200-1206

  5. Transaxillary versus transfemoral access as default access in TAVI: A propensity matched analysis

    International Journal of Cardiology

2022

  1. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis

    JAMA Dermatology, Vol. 158, Núm. 5, pp. 561-572

  2. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

    Prostate cancer and prostatic diseases, Vol. 25, Núm. 4, pp. 755-761

  3. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

2021

  1. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

    Hellenic Journal of Cardiology, Vol. 62, Núm. 2, pp. 152-157

  2. Final five-year results of the REMEDEE Registry: Real-world experience with the dual-therapy COMBO stent

    Catheterization and Cardiovascular Interventions, Vol. 98, Núm. 3, pp. 503-510

  3. Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes

    Journal of the American College of Cardiology, Vol. 77, Núm. 22, pp. 2777-2791

  4. One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration

    Cardiovascular Drugs and Therapy, Vol. 35, Núm. 2, pp. 309-320

  5. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (Nature Genetics, (2021), 53, 1, (65-75), 10.1038/s41588-020-00748-0)

    Nature Genetics

  6. Severe Valvular Heart Disease and COVID-19: Results from the Multicenter International Valve Disease Registry

    Structural Heart, Vol. 5, Núm. 4, pp. 424-426

  7. Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration

    Catheterization and Cardiovascular Interventions, Vol. 97, Núm. 5, pp. 797-804

  8. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

    Nature Genetics, Vol. 53, Núm. 1, pp. 65-75

  9. Triglycerides and Residual Atherosclerotic Risk

    Journal of the American College of Cardiology, Vol. 77, Núm. 24, pp. 3031-3041

2020

  1. 1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry

    IJC Heart and Vasculature, Vol. 31

  2. 1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration

    Cardiovascular Revascularization Medicine, Vol. 21, Núm. 12, pp. 1542-1547